Nucala is manufactured by GlaxoSmithKline (GSK) [1]. The company has manufacturing facilities in various locations globally.
What is Nucala used for?
Nucala, also known by its generic name mepolizumab, is a medication used to treat severe eosinophilic asthma [2]. It is also approved for treating other eosinophil-driven conditions, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) [3].
When does Nucala's patent expire?
The patent expiry for Nucala is subject to various patents covering the drug substance, formulations, and methods of use. DrugPatentWatch.com tracks these patents and their expiry dates. Information on specific patent expiry dates can be found on platforms like DrugPatentWatch.com [4].
Can generic versions of Nucala be made?
The development of generic versions of Nucala depends on the expiry of relevant patents and any associated regulatory exclusivities. Once these protections lapse, companies may be able to seek approval for generic versions.
How does Nucala work?
Nucala is a monoclonal antibody that targets interleukin-5 (IL-5) [2]. IL-5 is a protein that plays a key role in the inflammation associated with eosinophilic asthma by driving the production, survival, and activation of eosinophils. By blocking IL-5, Nucala reduces the number of eosinophils in the body [2][3].
What are the risks associated with Nucala?
Potential side effects of Nucala include allergic reactions, which can be serious. Patients may also experience infections [5].
What clinical data supports Nucala's use?
Clinical trials have demonstrated Nucala's efficacy in reducing asthma exacerbations and improving lung function in patients with severe eosinophilic asthma [2]. Studies have also shown its effectiveness in treating EGPA and HES [3].
Who are Nucala's competitors?
Other biologic medications are available for treating severe asthma, including those targeting different pathways like IgE or other interleukins. These include drugs such as Xolair (omalizumab), Fasenra (benralizumab), and Dupixent (dupilumab) [6].
---
1. GlaxoSmithKline. (n.d.). Manufacturing.
2. FDA. (2015, July 28). FDA approves NUCALA (mepolizumab) for severe asthma.
3. Nucala Prescribing Information. (n.d.).
4. DrugPatentWatch.com. (n.d.). Mepolizumab Patents.
5. Nucala. (n.d.). Important Safety Information.
6. Global Initiative for Asthma (GINA). (2023). GINA Report: Global Strategy for Asthma Management and Prevention.